



**THE FORUM**

For Collaborative Research<sup>SM</sup>

*Berkeley's Hub for Regulatory Science*

# Future of HIV Prevention Clinical Trials Summit

Johannesburg, South Africa


Wednesday, June 11, 2025



University of the Witwatersrand


**WITS RHI**

**UC Berkeley  
Public Health**




# **In Collaboration with Wits RHI**

**We thank Helen Rees and Sinead Delany-Moretlwe for their leadership in planning this event**



# Welcome, Housekeeping, and Overview

Logan Donaldson, *Forum for Collaborative Research*



# Housekeeping


# Please Note



- Breakfast, lunch, and drinks will be down the stairs out to the right
- The evening reception will be held below the current room
- Bathrooms just outside the room to the left
- Directory office downstairs, first door straight ahead and immediately to the left
- Daily shuttles provided to and from venue and 54 on Bath hotel

# Please Note

- Let us know if you have issues with the Wi-Fi, you should have received the Wi-Fi info at registration
- There are Zoom participants: please speak into a microphone, so they can hear you
- Act as if all microphones are always on
  - Private conversations should be held in the lobby or hallway
- This meeting is being recorded for notetaking purposes, and the recording will only be disbursed to registered participants




# Forum Overview

# Who we are



The Forum for Collaborative Research is a **public/private partnership** hosted by the **University of California, Berkeley**

We provide a **platform for ongoing multi-stakeholder dialogue** to address cutting-edge regulatory and policy issues



This is a **neutral, independent, safe space** where everyone has an equal voice

- Focus on developing consensus, increasing synergy and collaboration, and reducing duplication and uncertainty
- Active & engaged participation

This is a **closed meeting with no marketing and no press**

- Bring your expertise and Leave your “hat” at the door
- What’s said in the room stays in the room
- What’s said in the room is not for attribution

# HIV Forum Sponsors



This meeting is supported by:

# Gates Foundation

Additional HIV Forum sponsors (unrestricted grants – not linked to this event):



# Forum Team




- **Veronica Miller – Director**
- Jordan Cathey – Director of Operations, Business & Development
- **Christopher Berry – Senior Events and Operations Manager**
- **Alicia Jellinek – Program Financial Analyst**
- Mitchell Leus – Research Associate
- Shilpa Mitra – Research Associate
- **Logan Donaldson – Research Associate**
- Sehyr Khan – Research Associate
- **Ekene Osakwe – Research Associate**
- Edyth Dyer – Research Associate
- **Robin Schaefer – Post-Doctoral Scholar**
- Margot Yann – Lead Data Scientist
- Zachary Rooney – Research Associate
- **Michael Robertson – Program Advisor**
- Richard Haubrich – Program Advisor
- Jeffrey S. Murray – Program Advisor
- John Sninsky – Program Advisor
- Clair Gelfman – Program Advisor
- Kathy An – Student Intern
- **Alma Ebot – Student Intern**

# Wits RHI Team

- Shamim Ganie
- Deshni Naidoo
- Susie Cornell

And Many More!





# Summit Overview

# Overarching objective & focus

**Objective: Build consensus on ethical, acceptable, inclusive, feasible, and efficient HIV prevention clinical trial designs**

- **Consider context of future trial designs**
  - Evolving epidemiology
  - Changing standards of HIV prevention
  - Shifting funding and support for research
- **Recognize the importance of the African region in previous and future HIV research**
- **Consider clinical trials for different prevention modalities**
  - Small-molecule based PrEP
  - bnAbs for HIV prevention
  - HIV vaccines


**Benefit all stakeholders** involved and the **field in general**


# Summit overview



SAST	Day 1	SAST	Day 2
9:00AM	Session I: Welcome & summit overview	9:00AM	Welcome & housekeeping
10:00AM	Session II: State of HIV prevention clinical research	10:15AM	Session V: bnAbs for HIV prevention and HIV vaccines
11:15AM	Session III: Considerations for future trial designs	11:45AM	Lunch
12:45PM	Lunch & optional tour	1:00PM	Session VI: Clinical trial considerations for specific populations of interest
2:30PM	Session IV: Establishing efficacy in clinical trials	2:45PM	Session VII: Industry and funder panel
4:30PM	Moderated open discussion	3:15PM	Session VIII: Continued discussion and cross-cutting issues
5:30PM	Reception	4:45PM	Session IX: Next Steps/Action Items

# Process





**Thank you!**

**Wits RHI**

**Working Group Members**

**Sponsors**

**Organizing Teams**